Wen-juei J. Jeng
Linkou Branch
Linkou, TPQ, Taiwan
Linkou, TPQ, Taiwan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 159 publications
Can we de-escalate HCC surveillance after 10 years of HBV suppression on nucleos(t)ide analogues?
Journal: Journal of hepatology
Published: August 05, 2026
Phase 3 Results of Bepirovirsen Treatment for Chronic Hepatitis B Virus Infection.
Journal: The New England journal of medicine
Published: May 28, 2026
Letter: Dynamic HBcrAg and HBsAg After Nucleos(t)ide Analogue Cessation: Considerations in Interpreting Predictive Performance.
Journal: Alimentary pharmacology & therapeutics
Published: May 24, 2026
A randomized trial of viral vector and adjuvanted protein HBV therapeutic vaccine in people with chronic hepatitis B on nucleos(t)ide analogs.
Journal: Hepatology communications
Published: March 20, 2026
Severe hepatitis flares after antiviral withdrawal in chronic hepatitis B with lymphoma: Impact of rituximab.
Journal: JHEP reports : innovation in hepatology
Published: January 19, 2026
Reply: Revisiting FOXP3 expression and its prognostic implications in hepatocellular carcinoma.
Journal: Hepatology (Baltimore, Md.)
Published: August 17, 2025
Letter to the Editor: Peripheral Foxp3-high Tregs as a dual biomarker for HCC prognosis and immunotherapy response.
Journal: Hepatology (Baltimore, Md.)
Published: July 23, 2025
Letter: No Biochemical Relapse Is Associated With the Highest Off-Therapy HBsAg Loss Rate.
Journal: Alimentary pharmacology & therapeutics
Published: February 18, 2025
Switching to Entecavir >3 Months Before the End of Tenofovir-Based Therapy in Hepatitis B e Antigen-Negative Patients May Reduce Early Relapse and Hepatitis Flare.
Journal: The American journal of gastroenterology
Published: February 06, 2025
Last Updated: 09/26/2026